Neuralink Brain Chips Enable Quadriplegic Patients to Control Computers

Two Canadian patients with spinal cord injuries have successfully received implants of the Neuralink brain chip, allowing them to control computers using only their thoughts. This groundbreaking procedure marks the first clinical trial outside the United States for the technology developed by Elon Musk, which aims to bridge the gap between human brain activity and external devices.

The patients, both in their thirties and hailing from Ontario and Alberta, underwent the surgeries at Toronto Western Hospital under the guidance of Dr. Andres Lozano, a leading neurosurgeon at the University Health Network. The surgeries occurred on August 27 and September 3, 2025. Both individuals have limited or no manual dexterity due to their conditions. Remarkably, they were able to manipulate a computer cursor almost immediately after the procedure.

Dr. Lozano explained that electrodes were implanted in the motor areas of the patients’ brains, which capture neuronal signals and convert them into commands for external devices. He noted, “The first patient was able to control a cursor by just thinking within minutes. It is extremely rapid. The signals are decoded and the artificial intelligence reads the signals and then translates them into movement on the cursor.”

The promise of brain-computer interface (BCI) devices is not limited to Neuralink. Other companies, including New York-based Synchron, are also conducting trials in this rapidly evolving field. While the potential benefits of such technology are exciting, experts urge caution regarding expectations.

Barry Munro, chief development officer of the Canadian Spinal Research Organization, has been quadriplegic since a diving accident 38 years ago and has dedicated his life to spinal cord injury research. He has also assisted in recruiting participants for Neuralink’s U.S. trial. Munro shared his concerns, noting that the first patient who received the device in the United States experienced complications when the implant began to shift weeks after surgery. Despite these challenges, he acknowledged the technology’s potential, stating, “We ain’t there yet, that’s all.”

The Canadian trial participants will be monitored for a minimum of one year, with plans to enroll an additional four patients who are either paralyzed due to spinal cord injuries or diagnosed with Amyotrophic Lateral Sclerosis (ALS). The research team aims to evaluate both the safety of the implants and their impact on the patients’ quality of life. They will be vigilant for potential side effects, including seizures, infections, or strokes.

As these patients progress, they will learn to type on a computer without using a keyboard, and they have already begun playing video games. Dr. Lozano emphasized that this trial represents a preliminary step towards understanding the broader applicability of the technology. He stated, “The device right now is a cursor, but in the future you could drive a car, you could drive your wheelchair, you could drive a robot.”

The initial findings from the Canadian trial have sparked interest and optimism within the scientific community. As the technology develops, it could pave the way for transformative advancements in assistive devices for individuals with mobility impairments. The journey to refine and expand this technology continues, with many watching closely to see how these groundbreaking efforts unfold.